RNASE1 and neoplasm: Our study provides an understanding of the cross-talk between tumor and immune cells in the TME, and identifies RNase1 as a potential plasma biomarker to overcome tumor-associated macrophage (TAM)-mediated immunosuppression in HCC patients.